Table 1.
Characteristics of the eligible papers
| Paper | Authors | Vaccine | Design | Study Period | Definition of VE | Age groups (year) | Reference |
|---|---|---|---|---|---|---|---|
| 1 | Young-Xu Y et al. | BNT162b2 and mRNA1273 | Test-negative study | 14 December 2020 to 14 March 2021 | SARS-CoV-2 infection (lab-confirmed, regardless of symptoms) ≥14 days after 2nd dose | 18–64 and ≥65 | 8 |
| 2 | Tenforde MW et al. (#1) | BNT162b2 and mRNA1273 | Test-negative study | 1 January 2021 to 26 March 2021 | Hospitalization due to COVID-19 ≥ 14 days after 2nd dose | ≥65 | 9 |
| 3 | Moline HL et al. | BNT162b2 and mRNA1273 | Observational cohort study | 1 February 2021 to 30 April 2021 | Hospitalization due to COVID-19 ≥ 14 days after 2nd dose | 65–74, and ≥75 | 10 |
| 4 | Tenforde MW et al. (#2) | BNT162b2 and mRNA1273 | Test-negative study | 11 March 2021 to 5 May 2021 | Hospitalization due to COVID-19 ≥ 14 days after 2nd dose | 18–49, 50–64, and ≥65 | 11 |
| 5 | Thompson MG et al. | BNT162b2 and mRNA1273 | Test-negative study | 1 January 2021 to 22 June 2021 | Hospitalization due to COVID-19 ≥ 14 days after 2nd dose | 50–64, 65–74, 75–84 and ≥85 | 12 |
| 6 | Bajema KL et al. | BNT162b2 and mRNA1273 | Test-negative study | 1 February 2021 to 6 August 2021 | Hospitalization due to COVID-19 ≥ 14 days after 2nd dose | 18–64 and ≥65 | 13 |
| 7 | Tartof SY et al. | BNT162b2 | Observational cohort study | 14 December 2020 to 8 August 2021 | SARS-CoV-2 infection (lab-confirmed, regardless of symptoms), or hospitalization due to COVID-19 ≥ 7 days after 2nd dose | 16–44, 45–64, and ≥65 | 14 |
| 8 | Cohn BA et al. | BNT162b2 and mRNA1273 | Observational cohort study | 1 July 2021 to 31 October 2021 | Death due to COVID-19 ≥ 14 days after 2nd dose | 18–64 and ≥65 | 15 |